ANP.AX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 Jan 2024 @ 12:56):

Stats
今日成交量	869 280
平均成交量	548 968
市值	52.29M
EPS	$0 ( 2024-02-19 )
下一个收益日期	( $0 ) 2024-07-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.90
ATR14	$0.00300 (5.36%)

音量相关性

長: -0.22 (neutral)

短: -0.74 (moderate negative)

Signal:(44.832) Neutral

Antisense Therapeutics 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Antisense Therapeutics 相关性 - 货币/商品

-0.68
( moderate negative )

-0.56
( weak negative )

0.00
( neutral )

0.47
( neutral )

Antisense Therapeutics 财务报表

Annual	2022
营收:	$1.58M
毛利润:	$1.55M (97.91 %)
EPS:	$-0.0179

FY	2022
营收:	$1.58M
毛利润:	$1.55M (97.91 %)
EPS:	$-0.0179

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.00920

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0209

Financial Reports:

No articles found.

Antisense Therapeutics

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.